Contact Us
Company Overview
|
Pipeline / Clinical Trials
|
Science & Discovery
|
Business Development
|
Investors
Overview
|
Stock Data
|
Governance
|
SEC Filings
|
News & Events
|
Presentations
|
Fundamentals
|
Information Request
Press Release Archive
Press Release Archive
2010
> 2009 >
2008
>
2007
>
2006
>
2005
>
2004
>
2003
>
2002
>
2001
December 9, 2009
RegeneRx Announces Final Clinical Results from Phase I Trial with RGN-352
October 2, 2009
Promising Clinical Data with RegeneRx's Tβ4 Drug Candidates Presented on Second Day of Thymosin Meeting
October 1, 2009
Scientists Report Impressive Research Results with Tβ4 on First Day of Thymosin Meeting
September 30, 2009
RegeneRx Announces Offerings of Common Stock in Aggregate Amount of $4.7 Million
September 29, 2009
RegeneRx's Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
September 24, 2009
RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease
September 4, 2009
RegeneRx President and CEO to Speak at Rodman & Renshaw Annual Global Investment Conference
August 24, 2009
RegeneRx Receives Notice of Allowance in Europe for Key Patent Related to Inhibition and Reversal of Skin Aging
July 15, 2009
Wayne State University researcher tests eye drops as chemical weapons aid
June 22, 2009
RegeneRx Working with U.S. Military to Test Tβ4 Against Exposure to Chemical Agents in the Eye
June 12, 2009
RegeneRx Receives Australian Patent for Compositions and Methods for Delivering Tβ4 and Its Analogues and Derivatives
May 29, 2009
NYSE Amex Accepts RegeneRx Plan of Compliance
May 4, 2009
RegeneRx Receives Australian Patent for Treating Eye Disorders with Tβ4
April 30, 2009
RegeneRx Receives Listing Notice from NYSE Amex
April 13, 2009
RegeneRx Announces Financing Transaction and Cost Reduction Program
April 4, 2009
Tβ4 Identified as Key Molecule Capable of Triggering Stem Cells to Repair Damaged Adult Heart
April 2, 2009
Ophthalmology Times Publishes Article on RGN-259 and Corneal Wound Healing
March 26, 2009
RegeneRx Reports Phase II Venous Stasis Trial Results
March 2, 2009
RegeneRx Completes Enrollment and Dosing of Phase I Safety Trial for Potential Heart Drug
February 26, 2009
RegeneRx Updates on Phase II Venous Stasis Trial
February 23, 2009
Clinical Results with RegeneRx's Ophthalmic Drug Candidate Subject of Oral Presentation at 2009 ARVO Meeting
February 4, 2009
RegeneRx President and CEO to Speak at 11th Annual BIO CEO & Investor Conference
January 21, 2009
RegeneRx to Shift Ophthalmic Clinical Development Strategy
January 13, 2009
RegeneRx Receives Patent for Reversal of Skin Aging in Japan
January 9, 2009
RegeneRx Reports Phase II Pressure Ulcer Trial Results
home
|
Contact Us
|
Resources
|
Site Map
|
Search
